Travere Therapeutics, Inc. TVTX Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s change in deferred revenue?
- Travere Therapeutics, Inc. (TVTX) reported change in deferred revenue of $0 in Q1 2026.
- How has Travere Therapeutics, Inc.'s change in deferred revenue changed year-over-year?
- Travere Therapeutics, Inc.'s change in deferred revenue increased by 100.0% year-over-year, from -$1.35M to $0.
- What is the long-term trend for Travere Therapeutics, Inc.'s change in deferred revenue?
- Over 3 years (2021 to 2024), Travere Therapeutics, Inc.'s change in deferred revenue has grown at a -46.6% compound annual growth rate (CAGR), from $40.15M to -$6.12M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.